Thursday, 5 November 2026European Markets

SIPEF And EUROPRIS Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(VIANEWS) - SIPEF (SIP.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Defensive sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SIPEF (SIP.BR) €53.10 5.61% 9.39%
EUROPRIS (EPR.OL) kr60.00 4.44% 33.76%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SIPEF (SIP.BR)

5.61% Forward Dividend Yield and 9.39% Return On Equity

Sipef NV operates as an agro-industrial company. It operates through Palm, Rubber, Tea, and Bananas and Plants segments. The company offers crude palm oil, palm kernels, and palm kernel oil; ribbed smoked sheets, and scraps and lumps; cut, tear, and curl tea; and bananas and plants from Ivory Coast. It has operations in Indonesia, Papua New Guinea, Ivory Coast, Singapore, Europe, and internationally. The company was incorporated in 1919 and is headquartered in Schoten, Belgium.

Earnings Per Share

As for profitability, SIPEF has a trailing twelve months EPS of €6.83.

PE Ratio

SIPEF has a trailing twelve months price to earnings ratio of 7.77. Meaning, the purchaser of the share is investing €7.77 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.39%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 12.5%, now sitting on 496.25M for the twelve trailing months.

Yearly Top and Bottom Value

SIPEF's stock is valued at €53.10 at 02:30 EST, way below its 52-week high of €62.50 and higher than its 52-week low of €51.70.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Jul 3, 2023, the estimated forward annual dividend rate is 3 and the estimated forward annual dividend yield is 5.61%.

More news about SIPEF.

2. EUROPRIS (EPR.OL)

4.44% Forward Dividend Yield and 33.76% Return On Equity

Europris ASA operates as a discount variety retailer in Norway. It sells own brand and branded merchandise, including groceries, animal, leisure time, home and interior, house and garden, kitchen, clothes, storage, and personal care products. The company also offers its products through online shopping. Europris ASA was incorporated in 2011 and is headquartered in Rolvsøy, Norway.

Earnings Per Share

As for profitability, EUROPRIS has a trailing twelve months EPS of kr5.82.

PE Ratio

EUROPRIS has a trailing twelve months price to earnings ratio of 10.31. Meaning, the purchaser of the share is investing kr10.31 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.76%.

Volume

Today's last reported volume for EUROPRIS is 162683 which is 5.13% below its average volume of 171486.

More news about EUROPRIS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com